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The mechanisms by which mutations in the presenilins
(PSEN) or the amyloid precursor protein (APP) genes
cause familial Alzheimer disease (FAD) are controversial.
FAD mutations increase the release of amyloid b (Ab)42
relative to Ab40 by an unknown, possibly gain-of-toxic-
function, mechanism. However, many PSEN mutations
paradoxically impair c-secretase and ‘loss-of-function’ me-
chanisms have also been postulated. Here, we use kinetic
studies to demonstrate that FAD mutations affect Ab gen-
eration via three different mechanisms, resulting in qua-
litative changes in the Ab proﬁles, which are not limited to
Ab42. Loss of e-cleavage function is not generally observed
among FAD mutants. On the other hand, c-secretase in-
hibitors used in the clinic appear to block the initial
e-cleavage step, but unexpectedly affect more selectively
Notch than APP processing, while modulators act as
activators of the carboxypeptidase-like (c) activity.
Overall, we provide a coherent explanation for the effect
of different FAD mutations, demonstrating the importance
of qualitative rather than quantitative changes in the Ab
products, and suggest fundamental improvements for cur-
rent drug development efforts.
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Introduction
A central and still unresolved debate with important therapeu-
tic implications in the ﬁeld of Alzheimer disease (AD) research
revolves around the question of how mutations in presenilin
(PSEN), the catalytic core of the g-secretases (De Strooper et al,
1998), cause disease. The g-secretases are intramembrane
cleaving protein complexes (Hebert et al, 2004; Shirotani
et al, 2004) responsible for the generation of amyloid b (Ab)
from the amyloid precursor protein (APP). Ab peptides of
different lengths accumulate in amyloid plaques in the AD
brain. More than 150 familial Alzheimer disease (FAD)
mutations have been mapped to the genes encoding PSEN1
or PSEN2 (http://www.molgen.ua.ac.be/ADMutations), point-
ing to a crucial role of the g-secretase complexes in the disease.
Apart from PSEN, a mature and active g-secretase complex
consists of three additional subunits: Nicastrin (Nct), PSEN
enhancer 2 (Pen-2), and either anterior pharynx 1 (APH-1)
A or B (for a review, see Tolia and De Strooper, 2009). The
g-secretase complexes proteolyse type 1 transmembrane
proteins, among them the APP, the Notch receptors and
ligands, the Erb4 receptor and N-Cadherin (Wakabayashi and
De Strooper, 2008).
As a rule, FAD PSEN mutations increase the relative
amount of Ab42 versus Ab40 in in vivo and in vitro para-
digms (Borchelt et al, 1996; Duff et al, 1996; Scheuner et al,
1996; Murayama et al, 1999), which led to propose that PSEN
mutations act via a toxic gain-of-function mechanism.
However, more reﬁned analyses have made clear that the
change in Ab ratio does not necessarily reﬂect an increase in
Ab42 production, but can also be the consequence of a
decrease in Ab40 levels. Actually, many mutations reduce
one or both products of the g-secretase in steady-state
conditions (Song et al, 1999; Bentahir et al, 2006; Shen and
Kelleher, 2007; Shimojo et al, 2007; Heilig et al, 2010). These
observations have led to an opposite hypothesis in which
FAD mutations in PSEN cause dementia through a loss of
function of g-secretase, resulting in decreased proteolytic
processing of different substrates and compromising
intracellular signalling pathways (Shen and Kelleher, 2007;
Kelleher and Shen, 2010). In fact, the current model for
g-secretase successive proteolysis (Takami et al, 2009) may
link a loss of function to misprocessing of APP and abnormal
generation of Ab (De Strooper, 2007; Wolfe, 2007). However,
the fact that less efﬁcient proteolytic processing of APP may
lead to alterations in the Ab proﬁle and AD is contraintuitive
in the light of the classical amyloid hypothesis, which stresses
the importance of quantitative accumulation of either total
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report has shown that reduced g-secretase activity does not
increase the production (accumulation) of longer Ab peptides
(Quintero-Monzon et al, 2011).
Importantly, the biophysical and biochemical properties of
Ab vary strongly with its length. Longer Ab42 has a much
stronger tendency to aggregate than the shorter Ab40 (Jarrett
and Lansbury, 1993; Jarrett et al, 1993). Furthermore, the
relative ratio of Ab40 to Ab42 inﬂuences strongly the
biological effects of the Ab mixture in vitro and in vivo,
even when total Ab amounts are kept equal (Kuperstein
et al, 2010). Whereas Ab40 appears to act protectively in
various toxicity assays (Wang et al, 2006; Kim et al, 2007),
longer Ab peptides promote aggregation and neurotoxicity
(McGowan et al, 2005). In fact, it has been suggested that the
ratio (Ab42/Ab40) is more important than the absolute
amounts of Ab42 (Tanzi and Bertram, 2005). Similar to
Ab42, Ab43 is potently amyloidogenic and neurotoxic
(Saito et al, 2011). While it is commonly found in AD
brains (Welander et al, 2009), its potential relevance in
disease was only recently addressed (Saito et al, 2011).
Thus, qualitative changes in Ab (De Strooper, 2007; Wolfe,
2007) are at least as important as the quantitative alterations
proposed by the original amyloid hypothesis (Hardy and
Selkoe, 2002).
In contrast, the ‘simple’ loss-of-function hypothesis proposes
that Ab alterations are only an epiphenomenon of the PSEN
mutations, and that inefﬁcient cleavage of membrane proteins
by g-secretase complexes is the fundamental upstream cause of
the neurodegenerative process (Shen and Kelleher, 2007;
Kelleher and Shen, 2010). This hypothesis ﬁnds support in (a)
experimental results with Psen knockout mice (Saura et al,
2004), where progressive neurodegeneration occurs without
Ab deposition, and (b) in three case reports in which missense
mutations in PSEN genes displayed neurodegenerative clinical
phenotypes but no Ab accumulation (discussed in Shen and
Kelleher, 2007; Kelleher and Shen, 2010). However, this last
argument has been considerably weakened by follow-up
studies showing that neurodegeneration was likely caused by a
second mutation in the progranulin gene in one case (Boeve
et al, 2006), whereas in a second case abundant amyloid
deposition in the frontal lobe appeared at autopsy (for further
discussion, see Bergmans and De Strooper, 2010).
On the other hand, recent observations in patients suffer-
ing from familial acne inversa in China (Wang et al, 2010) and
independently in Great Britain (Pink et al, 2011) raise doubts
about the validity of the ‘simple’ g-secretase loss-of-function
hypothesis. This condition appears to be associated with the
haploinsufﬁciency of g-secretase subunit genes (Nicastrin,
Pen2) and most likely involves a deﬁciency in Notch cell
signalling. However, none of the acne-affected individuals
had AD symptoms. These observations indicate that reduced
g-secretase activity is not sufﬁcient to cause AD, although
further follow-up studies in these families are needed.
Alternative mechanisms for the loss-of-function hypothesis
have been proposed over the years (for an overview, see De
Strooper and Annaert, 2010). For instance, several reports
indicate alterations in subcellular trafﬁcking or turnover of
selected membrane proteins (Wilson et al, 2004; Esselens
et al, 2004) or defective acidiﬁcation of phagolysosomal
compartments associated with PSEN loss of function (Lee
et al, 2010). In addition, disturbances in cellular Ca
2þ
homeostasis by direct effects on the Ca
2þ leakage function
of PSEN (Zhang et al, 2010) or indirect effects on Ca
2þ
signalling pathways (reviewed in Bezprozvanny and
Mattson, 2008) have been associated to PSEN loss of
function. However, these hypotheses do not provide an
explanation for the mutations in APP and also do not take
into account that all tested FAD mutations affect the prime
function of PSEN, which is proteolysis.
From this brief overview it is clear that further in-depth
investigation of the effects of clinical mutations on the
function and structure of g-secretase is required, especially
given the relevance of such analysis for further drug
development.
Addressing this important question implies multidisciplin-
ary approaches, in which deep structural and functional
studies dissect the mechanisms of FAD mutations. Solving
the 3D-structure of the protease complex would allow study-
ing how FAD mutations affect the structure, and possibly the
function. However, this is a huge challenge as important
technical and experimental barriers need to be overcome.
On the other hand, dissecting g-secretase activity by kinetic
analysis can yield important mechanistic insights into how
FAD mutants regulate enzyme function.
In vitro reconstitution of g-secretase activity has provided
initial insights into the enzymatic mechanism. Ihara and co-
workers have provided compelling evidence for sequential
processing of substrates by g-secretase (Sato et al, 2003; Qi-
Takahara et al, 2005; Kakuda et al, 2006; Yagishita et al,
2008). The most direct evidence was the identiﬁcation of
particular tri- and tetra-peptides generated from the APP-CTF
stub by the g-secretase (Takami et al, 2009). Their
model proposes that APP can be sequentially cut along
two production lines: Ab494Ab464Ab434Ab40 and
Ab484Ab454Ab424Ab38 (Figure 1A). Accordingly, the
endoproteolytic activity (ﬁrst e-cleavage) releases the APP
intracellular domain (AICD) and Ab48 or Ab49. These long
Abs are then shortened by consecutive carboxypeptidase-like
g-cleavages, which progressively decrease Ab hydrophobicity
and increase the probability of its release into the extracel-
lular environment. In agreement, it has been shown that the
endoproteolytic cleavage site determines the product line
preference of the g-secretase in vivo (Funamoto et al, 2004),
and therefore the series of Ab products. Also, presenilinase
cleavage (the autocatalytic activation of PSEN) results in the
generation of tripeptides in accordance with this model
(Fukumori et al, 2010). The e-cleavage in the APP substrate
is analogous to the Notch S3 cleavage site (Sastre et al, 2001;
Weidemann et al, 2002) and most likely other g-secretase
substrates are processed in similar ways.
In the current study, we used a cell-free assay to analyse
how clinical mutations in PSEN1, PSEN2 and APP affect the
activity of the g-secretase complex. Dissection of the different
activities of the g-secretase complex allowed us to reach a
coherent explanation for the effects of the tested FAD muta-
tions. We coupled kinetic studies of the endopeptidase activ-
ity to the analysis of the carboxypeptidase-like cleavage to
show that FAD mutations have widely variable effects on the
efﬁciency of the ﬁrst cleavage, which releases the intracellu-
lar signalling domains of substrates. This observation rules
out an impairment in the endopeptidase (e) mechanism as
necessary for the pathological effect of FAD mutations. In
contrast, all FAD PSEN and APP mutations alter the proces-
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mechanisms.
Results
FAD–PS1 mutations do not consistently impair
the endopeptidase activity of the c-secretase
We analysed the effects of FAD mutations PSEN1-Y115H, -
M139V, -L166P, -I213T, -G384A and delta-exon9 (DE9) on the
kinetic constants of the e-cleavage of APP, Notch, ErB4 and N-
Cadherin substrates. The selected mutations are spread
throughout the PSEN1 primary sequence (Figure 1B).
Importantly, blockage by the transition state analogue
L-685,458 (TSA, InhX) demonstrated the speciﬁcity of the
assays (Supplementary Figure 1A). To determine the kinetic
constants of wt and FAD g-secretase complexes, we used
CHAPSO-extracted membranes from Psen1/2
 / , rescued
with wt or FAD-mutant PSEN1 as source of enzyme
(Figure 1C) and puriﬁed APP C99–3XFlag, Notch–3XFlag,
Erb4–3XFlag or N-Cadherin–3XFlag as substrates.
Figure 1 FAD–PSEN1 mutations do not consistently decrease the enzymatic efﬁciency of the endopeptidase cleavage. (A, B) Schematic
overviews of APP processing and location of FAD–PSEN1 mutations used in the current study. (C) Expression levels of Nct, PSEN1–NTF,
PSEN1–CTF and Pen-2 in Psen1/2
 /  mEFs transduced with human wt or FAD–PSEN1 mutants using a replication-defective recombinant
retroviral expression system (Clontech) and selected with puromycin (5mg/ml). Western blotting and densitometric analysis of the CHAPSO-
solubilized membrane proteins from the different PSEN1 cell lines indicate that wt and mutant PSEN1 rescued g-secretase complex to similar
extents. In order to determine speciﬁc activities for the wt or FAD complexes, g-secretase activities were normalized to PSEN CTF fragment
levels or full-length PS1 levels for the DE9 mutant. (D) Kinetic curves for wt and PS1–FAD mutants using puriﬁed APP-C99-3XFLAG or Notch-
3XFLAG substrates (mean±s.e.) or (F) ErB4-3XFLAG and N-Cadherin-3XFLAG substrates (mean±s.d.). Detergent-extracted membranes were
incubated in 0.25% CHAPSO reaction buffer with varying concentrations of puriﬁed substrate for 4h at 371C. In vitro generated ICD-3XFLAG
were analysed by quantitative western blot analysis (see Materials and methods). (E) FAD–PSEN1 e-enzymatic efﬁciencies for APP-C99 and
Notch substrates (mean±s.e.). Enzymatic efﬁciencies unequivocally demonstrate that loss of function at the e-cleavage is not a constant
among PSEN1 mutations. (G) FAD–PSEN1 mutations that did not affect the generation of NICD did not change signiﬁcantly the processing of
ErB4 (mean±s.d.) either. In contrast, N-Cadherin processing was signiﬁcantly upregulated by the M139V (mean±s.d.). (E, G) Experiments
were repeated 3–5 times. Statistical signiﬁcance of the data was tested with one-way analysis of variance (ANOVA) and Dunnett’s post test,
taking the corresponding WT efﬁciency as control group, *Po0.05.
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(Figure 1D and F), and Km (afﬁnity constant) as well as Vmax
(maximal velocity) were determined (Table I). Since g-secre-
tase activities are normalized to enzyme levels, Vmax can be
taken as kcat and enzymatic efﬁciencies calculated as kcat/
Km. The results reveal diverse effects of the FAD–PSEN1
mutations on this important kinetic parameter. Y115H,
L166P and G384A mutants decrease g-secretase efﬁciencies
by 75% for both APP and Notch, while I213T and DE9 only
affect APP, and M139V does not show any effect on the
e-cleavage (Figure 1E). Moreover, FAD–PSEN1 mutations
that do not affect Notch endoproteolysis do not impair ErB4
cleavage either, while only the M139V signiﬁcantly increases
the processing of N-Cadherin (Figure 1G). Thus, the tested
FAD–PSEN1 mutations have no consistent inhibitory effect on
the endoproteolytic cleavage of g-secretase substrates, indi-
cating that reduced release of intracellular domains and
signalling cannot explain their AD-causing effects.
FAD–PSEN mutations impair the fourth c-secretase
cleavage in both product lines
Next, we asked whether FAD–PSEN1 mutations lead to APP
misprocessing at the g-cleavage sites. We use Ihara’s model
(see Introduction) for further description of our work since it
explains very well our observations. Kinetic analysis of the
carboxypeptidase-like activity is challenging to perform since
controlling substrate concentrations, that is, the intermediary
Ab products, is experimentally not possible yet. Nevertheless,
we measured two g-products in each production line: Ab43,
Ab42, Ab40 and Ab38 (Figure 1A) at saturating APP-substrate
concentration. Thus, substrates (Ab43 and Ab42) and pro-
ducts (Ab40 and Ab38) of the fourth g-secretase cleavage in
both pathways are analysed and provide a relative number
for the g-cleavage efﬁciency. Importantly, as some of the
clinical mutants affect the e-cleavage, we normalized the
Ab product levels (Ab38, Ab40, Ab42 or Ab43) towards
total AICD (Figure 2A and B). AICD reﬂects the total initial
Ab substrate (Ab49þAb48) produced and processed in each
reaction. Low Ab40 and Ab38 levels and high, long Ab levels
(4Ab42) are found in all the FAD-linked mutations tested,
including the M139V, which does not affect the e-efﬁciency.
Interestingly, the M139V mutation affects the processing of
APP only at the level of Ab, indicating that endo- and
carboxypeptidase-like activities of the g-secretase can be
dissociated.
Total ‘secreted’ Ab, deﬁned as the sum of Ab38, Ab40,
Ab42 and Ab43, decreases signiﬁcantly in the Y115H, L166P,
DE9 and G384A mutations (Figure 2B), implying the con-
comitant accumulation of longer Ab precursors generated in
cycles 2 and 3. Qualitative analysis of the Ab proﬁles in urea-
based SDS–PAGE conﬁrmed this observation (Figure 2C and
Supplementary Figure 2B). We ﬁnally determine product/
substrate ratios for the fourth enzymatic turnover (Ab38/
Ab42 and Ab40/Ab43) (Figure 2D), which demonstrates that
the FAD–PSEN1 mutations investigated here dramatically
impair the fourth g-secretase cleavage in both product lines.
Our data imply that FAD–PSEN1 mutations cause AD by
qualitative shifts in Ab proﬁles and not by general loss of
function of the enzyme complex (Shen and Kelleher, 2007;
Wolfe, 2007). The dysfunction at the carboxypeptidase-like
activity of the complex not only explains the widely
documented increase of the Ab42/Ab40 ratio, but also
suggests a pathological relevance of an increase in Ab43,
which has been reported recently in vivo with the PSEN–
R278I (Saito et al, 2011).
In order to conﬁrm our in vitro data, mouse embryonic
ﬁbroblasts (MEFs) derived from Psen1/2
 /  mice
(Herreman et al, 2000) rescued with human WT– or FAD–
PSEN1 mutants were transiently transduced with APPsw.
Secreted Ab levels (sAb) were quantiﬁed by enzyme-linked
immunosorbent assay (ELISA). Figure 2E shows drastic re-
ductions in the Ab38/Ab42 and Ab40/Ab43 ratios for all
FAD–PSEN1 mutations, conﬁrming that the fourth enzymatic
turnover of the g-secretase is actually impaired in cells
(native g-secretase conditions). To investigate whether
FAD–PSEN2 mutations also affect the fourth enzymatic turn-
over of the g-secretase, we performed kinetic analyses with
human WT–PSEN2 or FAD N141I–PSEN2 mutant. The effect
of the mutation on the endopeptidase efﬁciency of the
g-secretase complex does not reach statistical signiﬁcance
(Figure 3A) (mean±s.e.: 100±39.9, n¼4 or 46.6±3.9, n¼3
for WT– or FAD N141I–PSEN2, respectively, two-tailed t-test,
P¼0.3). Although we cannot discard that this difference is
biologically meaningful, the effect on the fourth catalytic
cycle is unequivocal. In particular, the Ab40 product was
decreased to undetectable levels (Figure 3B). Similar to the
mutations in PSEN1, the N141I–PSEN2 reduces the Ab38/
Table I Kinetic parameters for human PSEN1 g-secretase complexes using APP-C99, Notch, ErB4 or N-Cadherin as substrates
APP-C99 substrate Notch substrate Erb4 substrate N-Cadherin substrate
Km±s.e.,
mM
Vmax±s.e.,
pM/min
Km±s.e.,
mM
Vmax±s.e.,
pM/min
Km±s.d.,
mM
Vmax±s.d.,
pM/min
Km±s.d.,
mM
Vmax±s.d.,
pM/min
PS1 wt 0.40±0.05 175.6±8.4 1.08±0.17 95.7±7.5 0.31±0.07 37.72±6.18 1.46±0.36 88.37±10.95
Y115H 0.81±0.18 113.3±11.3
a 3.92±1.97 86.49±31.4 — — — —
M139V 0.27±0.04
a 144.5±6.8
a 1.78±0.21
a 146.9±10.1
a 0.40±0.23 39.76±6.36 0.42±0.19
a 71.16±20.14
L166P 0.43±0.07 74.03±4.2
a 0.97±0.2 23.76±2.4
a ——— —
I213T 0.73±0.18 151.1±14.7 1.26±0.26 106.1±11.2 0.45±0.13 58.68±5.83
a 1.02±0.11 74.95±11.76
DeltaE9 0.82±0.18
a 133.5±13.5
a 0.67±0.24 42.8±6.5
a 0.33±0.06 40.84±8.12 1.70±0.43 21.97±8.39
a
G384A 0.92±0.18 93.87±8.7
a 1.85±0.42 71.04±9.5 — — — —
Kinetic values are derived from the curves displayed in Figure 1 and were determined by nonlinear curve-ﬁtting using GraphPad Prism 4
software (see Material and methods section).
a
Signiﬁcant changes according to the 95% CI (Po0.05). In vitro activity assays were performed using CHAPSO-extracted membranes from
Psen1/2
 /  mEFs stably transduced with human wt or FAD PSEN1 mutants and puriﬁed substrates-3XFlag, nX3.
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impairment in the carboxypeptidase-like activity.
Since high Ab43 and Ab42 (substrates in this cycle)
accumulate in vitro or are released in vivo, we speculate
that FAD–PSEN mutations promote a premature release of the
Ab43/Ab42 peptides.
FAD–APP mutations change the product line preference
of the c-secretase
We then asked whether similar mechanisms could explain
the effect of mutations in the APP substrate. The tested
mutations are located close to the g-secretase cleavage site,
that is, T43I, V44A, I45T, V46F and V46I (Figure 4A) and all
Figure 2 FAD–PSEN1 mutations impair the fourth enzymatic turnover. AICD levels (moles per min) generated by the wt or FAD mutant
complexes (A) were used to normalize Ab products (moles per min) in order to determine accurately Ab generation relative to C99 substrate. Ab
proﬁles (B) thus represent Ab products corrected for the initial endoprotease activities, plotted as percentage of the wt Ab products (mean±s.e.).
Soluble Ab (sum of Ab38, Ab40, Ab42 and Ab43 peptides) gives information about the efﬁciency of the g-cleavages: lower levels (o100%, grey
box) suggest that longer peptides (4Ab43) accumulate in the reactions. (C) In agreement with the ELISA quantiﬁcations, total Ab analysed in
urea-based gels show increments in Ab42 and Ab43, and reductions in Ab40 and Ab38 in FAD–PSEN1 mutations, relative to wt. (*) Indicates a
non product band that is present in the C99 substrate (see Supplementary Figure 2). (D)A b product/substrate ratios determined in vitro for the
FAD–PSEN1 mutations show an impairment at the fourth g-secretase turnover (mean±s.e.). Experiments in (B) and (D) were repeated 4–6
times. Statistical signiﬁcance of the data tested with one-way ANOVA and Dunnett’s post test taking the corresponding WT as control group;
*Po0.05, **Po0.01. (E)A b product/substrate ratios determined in vivo conﬁrm impairment at the fourth enzymatic cycle: wt or FAD–PSEN1
mEF cell lines were transiently transduced with APPswe, extracellular media collected at 24h after infection and sAb measured by ELISA
(mean±s.e.). Statistical signiﬁcance: n¼4, ANOVA and Dunnett’s post test, **Po0.01.
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except for the T43I mutation. Kinetic analyses of the
e-cleavage show that APP-T43I, V44A and -I45T mutants
produce less AICD per mol mutant APP compared to wt
substrate, while the other mutations do not affect the
e-enzymatic efﬁciency (Figure 4B and C). In order to analyse
accurately the Ab proﬁles from wt and FAD substrates, Ab
levels were normalized to the amount of AICD generated in
the reaction. FAD Ab levels, corrected for the initial amounts
of substrates, were then plotted as a percentage of the wt
enzyme (Figure 4D). Importantly, and in contrast to FAD–
PSEN, all the tested APP mutations do not affect Ab38/Ab42
or Ab40/Ab43 ratios (Figure 4E). The I45T mutant is the
exception, showing increased Ab38/Ab42 ratio, which would
be consistent with an impairment in the processing of Ab45
(mutant peptide) to Ab42. However, FAD–APP mutations
result in high Ab40/Ab38 compared to wt APP (Figure 4F).
Thus, all investigated mutations change the product line
preference by shifting APP processing towards the Ab38
production line. The APP-V44A and -I45T substrates in
particular show an additional accumulation of longer Ab
precursors (generated in cycles 2 and 3), as deduced from
soluble Ab in Figure 4D. The change in the product line can
be explained if these APP mutations shift the position of the
e-cleavage to generate more Ab48, the initial substrate in the
Ab38 production line. A neo-epitope antibody against
AICD50–99 (characterized in Supplementary Figure 3) was
generated, and allowed us to conﬁrm the product line pre-
ference (Figure 5A and B).
Figure 5C shows that the FAD–APP mutations
consistently shift the position of the e-cleavage towards
AICD49–99, promoting the Ab38 product line, and therefore
causing increments in the Ab42 and Ab38 products.
Importantly, HEK cells transiently transfected with
FAD-mutant C99 substrates increase the Ab42 and Ab38
levels in the extracellular medium while decreasing Ab40,
compared to control (wt C99) (Supplementary Figure 4).
Figure 4G actually shows that FAD–APP mutations change
the product line preference (Ab40/Ab38 ratio), but do not
alter the fourth enzymatic turnover (Ab38/Ab42 ratio).
Similar results were obtained from primary neuronal cultures
transiently expressing wt-, -I45T- or V46F-APP (Figure 4H).
These results indicate that our observations in the
cell-free assay can be extrapolated to the in vivo situation.
The FAD–APP data imply that promoting the Ab38 production
line is pathogenic.
It has been shown that small changes in the composition of
Ab mixes affect critically their aggregation kinetics and toxic
effects (Kuperstein et al, 2010), for example, a minor increase
in the Ab42:Ab40 ratio stabilizes toxic oligomeric species.
Since APP–FAD mutations increase both Ab42 and Ab38, we
asked whether Ab38 could have similar biophysical attributes
as Ab40, and therefore could alleviate the potential toxic
effects associated to Ab42. However, and in contrast to Ab40,
Ab38 has a predicted higher tendency to aggregate (http://
www.tango.crg.es) (Fernandez-Escamilla et al, 2004). To
validate this prediction, Ab-aggregation assays were
performed using thioﬂavine T ﬂuorescence as readout. We
compared the behaviours of Ab40 and Ab38 peptides by
analysing the aggregation properties of the Ab42:Ab40 (1:9)
and Ab42:Ab38 (1:9) mixes. In contrast to Ab40, Ab38 drives
aggregation of Ab mixes to higher extents (Supplementary
Figure 5A). We then compared the effects of different Ab
peptides on spontaneous synaptic transmission in the pri-
mary mouse hippocampal neurons. Our results show that
Ab38, similar to Ab42 and Ab43, but to a lesser extent, elicits
acute synaptotoxicity (Supplementary Figure 5B). Although
further work is needed to investigate the effects of Ab38
Figure 3 FAD–PSEN2 N141I impair the fourth enzymatic turnover.
(A) Kinetic curves for wt and PSEN2–FAD N141I mutant using
puriﬁed APP-C99-3XFLAG as substrate (mean±s.e.). (B)A b pro-
ﬁles represent Ab products corrected for the initial endoprotease
activities, plotted as % of the wt Ab products (mean±s.e.). Soluble
Ab (sum of Ab38, Ab40, Ab42 and Ab43 peptides) suggests
accumulation of longer peptides (4Ab43) in the mutant reactions.
(C)A b product/substrate ratios determined in vitro for the FAD–
PSEN2 mutation show an impairment at the fourth g-secretase
turnover (mean±s.e.). In (B) and (C) statistical signiﬁcance (two-
tailed t-test) is indicated by **Po0.005 and ***Po0.001. Note that
N141I abolishes Ab40 generation.
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widely divergent biophysical and biochemical properties.
Effects of inhibitors and modulators on the c-secretase
activity
Our data indicate that various mechanisms affecting the Ab
spectrum generated by g-secretase are responsible for the
pathogenic effects of the FAD mutations. Therefore, we asked
to what extent g-secretase inhibitors (GSI) and modulators
(GSM) that were tested in clinical trial or are under develop-
ment (De Strooper et al, 2010) affected the different
parameters discussed above. To evaluate g-secretase
inhibition under equal kinetic conditions, we took
advantage of the in vitro system and performed activity
assays at 1  Km substrate concentrations for APP C99 or
Notch substrates (0.4 and 1.1mM, respectively). Under these
conditions, the GSI semagacestat (LY-450139), begacestat
(Notch sparing GSI) and avagacestat (Notch sparing GSI)
efﬁciently inhibit Ab generation in the two production lines
(Supplementary Figure 6). However, semagacestat, which
failed in phase III trial (https://www.investor.lilly.com/
releasedetail2.cfm?releaseid¼592438) because of cognition
and skin problems, is more selective for Notch than for APP
(AICD IC50¼257.8nM and Notch intracellular domain
(NICD) IC50¼24.62nM (95% conﬁdence interval (CI):
190.2–349.5nM for APP and 15.74–38.51nM for Notch,
n¼5), whereas the transition state inhibitor L-685,458 affects
both substrates to an equal extent (Figures 6A and B).
Surprisingly, and in contrast to previous claims (Martone
et al, 2009; Gillman et al, 2011), the selectivity of both of the
‘Notch sparing’ GSI is not signiﬁcantly different for APP and
Notch substrates (Begacestat: AICD IC50¼61.71nM and
NICD IC50¼138.4nM (95% CI: 24.77–153.7nM for AICD
and 73.29–261.3 for NICD, n¼3) and BMS708163: AICD
IC50¼6.82nM and NICD IC50¼20.03nM (95% CI:
4.06–11.46nM for AICD and 7.76–51.7nM for NICD, n¼3))
(Figure 6C and D).
Recently, g-secretase modulators (GSM) have been evalu-
ated as an alternative to GSI (Weggen et al, 2001). GSM lower
Ab42 and increase Ab38, but the precise mechanism of action
has not been elucidated. One NSAID and two arylimidazole-
derived GSM (Oehlrich et al, 2010) (E-2012 and a close
analogue) did not affect the endopeptidase activity
(Figure 6E and Supplementary Figure 7A) but, as expected,
reduced Ab42 and increased Ab38. Analysis of the product/
substrate ratios for the fourth enzymatic turnover shows that
these drugs increase speciﬁcally this cycle (Figure 6F and
Supplementary Figure 7B) and act, therefore, in the opposite
way to the clinical FAD–PSEN mutations. The Ab ratios
indicated that the GSM evaluated in this study act mainly
on the fourth cycle of the Ab38 production line. In fact, our
data show them as activators of the g-secretase (GSA). Taking
into account the changes in the FAD–APPAb proﬁles and the
possibility that Ab38 may be part of the pathogenic mechan-
ism, it is crucial to evaluate to what extent the differential
effects of the GSA on the Ab production lines are problematic.
Discussion
This study settles several issues that have been heavily
debated in the literature. Dissection of the different activities
of the g-secretase complex allowed us to characterize the
mechanisms that are regulated in a consistent fashion by FAD
mutations in PSEN and APP. Previous reports have employed
steady-state analyses to evaluate the effect of these mutations
on the g-secretase. In general, these studies have employed
transfected cells to measure, in culture or in vitro, changes in
secreted product levels or follow the intracellular generation
of ICD products by coupling it to reporter systems. Although
these approaches are informative, they do not truly reﬂect the
kinetic features of the mutated g-secretase complexes or
APP substrates. For instance, substrate concentration and
accessibility is not controlled in such assays.
By analysing the catalytic efﬁciency of the g-secretase
complex (wt or mutated) in an in vitro assay, with both
enzyme and substrate in solution, we ﬁnd here that muta-
tions in PSEN1 and PSEN2 affect g-secretase at three levels.
We see (1) a variable inhibitory effect at the initial endopro-
teolytic e-cleavage step, which releases the intracellular do-
mains of substrates such as APP, Notch, Erb4 and N-
Cadherin. (2) A consistent effect on the consecutive carbox-
ypeptidase-like g-cleavage with all PSEN mutations causing a
‘premature’ release of (intermediary) substrates/products,
explaining why longer Ab is generated by these mutants.
Interestingly, our data suggest that both Ab42/Ab38 and
Ab43/Ab40 ratio increments are pathologically relevant. (3)
Additionally, some of the mutations in PSEN and all muta-
tions investigated here in the APP sequence (selected for their
close position to the g-cleavage site in APP) affect the initial
position of the e-site, that is, whether g-secretase cleaves
preferentially at position 49–50 or 51–50 in the APP sequence.
While these three mechanisms explain for the ﬁrst time the
abundantly documented increase in Ab42/Ab40 ratio asso-
ciated with all FAD mutations, they also provide a set of
entirely novel insights, as we discuss in the following
paragraphs.
Our study gives deﬁnite numbers on the catalytic efﬁciency
of the g-secretase complex at the e-site and unequivocally
shows that ‘loss of function’—lower catalytic efﬁciency—is
not consistent across the FAD mutations tested. In this regard,
we wish to draw attention to the fact that point mutations in
PSEN might affect protein stability, and therefore solubilization
of ‘less stable’ FAD g-secretase complexes might result in an
accentuated ‘loss of function’. Thus, we cannot exclude that the
enzymatic efﬁciencies of particular FAD complexes (less stable)
are underestimated in the conditions used in the current work,
which would even strengthen our conclusion that ‘loss of
function’ is not necessary for the FAD pathogenic mechanism.
Taking all into consideration, our results indeed rule out the
possibility that loss of intracellular signalling is necessary and
sufﬁcient to cause AD, as postulated by the ‘simple’ loss-of-
function hypothesis. Interestingly, the effects at the e-cleavage
site are also variable for different substrates tested (Km values
for APP, Notch, Erb4 and N-Cadherin, Table I), suggesting that
some of the clinical mutations affect the substrate speciﬁcity
mechanism. This is in particular clear for the M139V and DE9
mutations. DE9 removes part of the hydrophobic domain VII
(HDVII) of PSEN1, which is located in the active site of the
g-secretase (Tolia et al, 2008), while the M139 residue is located
in the second transmembrane domain of PSEN, which
contributes to the formation of the initial substrate-binding
site (Watanabe et al, 2010). On the contrary, our results show
that the L166P mutation affects the catalytic rate of the enzyme
but does not change the substrate speciﬁcity of the complex,
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in vivo are equally affected by different amino-acid
substitutions in the position 166 (Moehlmann et al, 2002).
We analysed in considerable detail the effects of FAD–
PSEN1 and FAD–PSEN2 mutations on the g-secretase (car-
boxypeptidase-like) mechanism that follows the initial
e-endoproteolytic cleavage of the APP substrate. We ﬁnd
that FAD–PSEN mutations impair dramatically the fourth
turnover in both Ab494Ab40 and Ab484Ab38 product
lines, resulting in decreased Ab40/Ab43 and Ab38/Ab42
Mechanisms of Alzheimer disease-causing mutations
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the decrease in short Abs( o40) reported in the cerebrospinal
ﬂuid of carriers of PSEN-A431E10 (Portelius et al, 2010) or the
alterations in the lengths of Ab peptides produced in vitro by
FAD–PSEN-containing complexes (Murphy et al, 2002).
Moreover, biophysical observations have shown that FAD–
PSEN mutations alter the conformation of the g-secretase
complex (Berezovska et al, 2005). Based on our biochemical
data we propose that changes in the active site of FAD–PSEN
mutations promote the premature release of the Ab43 or the
Ab42 peptides from the g-secretase complexes.
A third mechanism by which FAD–APP mutations act in
particular is the shift in the initial e-cleavage site resulting in
an increased Ab484Ab38. Likely, the product preference
results from differential docking modes of the APP substrate
into the active site. We conﬁrmed the shift towards
Ab484Ab38 in living cells expressing wt or mutant APP
substrates. This result corroborates our claim that the product
line preference is an intrinsic property of the g-secretase
complex that remains unaltered in our cell-free assay.
Interestingly, this shift in initial docking and production
lines is also observed in four of the six PSEN1 mutants
(Figure 5C and D). The fact that some FAD–PSEN1 mutations
combine these two mechanisms (impaired fourth cycle and
change in the product line preference) explains the direct and
indirect correlations between Ab38 and Ab42 levels reported
in the past (Czirr et al, 2008; Page et al, 2008).
Our study thus demonstrates that FAD mutations cause
qualitative changes in the Ab proﬁles by various mechanisms
(Bentahir et al, 2006; De Strooper, 2007), and that decreased
release of intracellular domains (Kelleher and Shen, 2010) is not
an essential part of the AD pathogenic mechanism.
Nevertheless, as indicated above, the most aggressive PSEN1
mutations, for example, the L166P, negatively impact the
Figure 5 Shift in the e-cleavage position contributes to the FAD-associated phenotype. (A) Detection of AICD50–99 and total AICD using a neo-
epitope antibody and the FLAG-M2 antibody, respectively. (B) SDS–PAGE/western blot analysis of AICD products from either wt and FAD
substrates (left panel) or wt and FAD–PSEN1mutants (right panel). Signals for the AICD50–99 neo-epitope antibody or the FLAG-M2 antibody are
shown in red and green, respectively. Overlapping neo-epitope and FLAG antibody signals are displayed in yellow. (C) AICD50–99/total AICD
ratios indicate that FAD–APP mutations promote the Ab38 product line by shifting the e-cleavage position. The I45Tcould not be included in
the analysis because of extremely low AICD signals (ND, not determined). (D) This pathogenic mechanism is also observed in some FAD–
PSEN1 mutations. Statistical signiﬁcance of the data (n¼5) tested with ANOVA and Dunnett’s post test, taking AICD generated in WT
conditions as control group; *Po0.05,**Po0.01.
Figure 4 FAD substrate mutations shift APP processing towards the Ab38 product line. (A) Schematic overview of FAD–APP mutations used in
this study. (B) Kinetic curves for the e-processing of APP. Detergent-extracted membranes from Psen1/2
 /  mEFs rescued with human wt
PSEN1 were incubated in 0.25% CHAPSO reaction buffer, with varying concentrations of puriﬁed wt or FAD–APP substrates. AICD-3XFLAG
levels were analysed by quantitative western blot analysis (see Materials and methods). (C) Enzymatic efﬁciencies for FAD–APP-C99 substrates
(mean±s.e.) prove that AICD generation is affected in three out of ﬁve FAD-mutant substrates. (D) FAD Ab product proﬁles suggest consistent
increments in Ab42 and Ab38. Soluble Ab levels (sum of Ab38, Ab40, Ab42 and Ab43 peptides) suggest accumulations of longer Ab peptides in
the g-processing of the V44A and I45T mutants. The T43I mutation disrupts the epitope for the anti-Ab43-speciﬁc antibody, thus neither Ab43
nor soluble Ab levels could be determined (ND). (E)A b product/substrate ratios reveal that APP mutations do not consistently affect the fourth
g-secretase turnover, but change the product-line preference as indicated by the Ab40/Ab38 ratio (F). (G)s A b in the conditioned media of
HEK293 cells transiently transfected with wt or FAD-C99 mutants were quantiﬁed by ELISA (see Supplementary Figure 4). sAb ratios indicate
that APP–FAD substrate mutants change the product-line preference towards the Ab484Ab38 (Ab40/Ab38) in living cells, but do not affect the
fourth catalytic turnover of the g-secretase (Ab38/Ab42) (mean±s.e., n¼5). (H) Primary cultured neurons were transduced with SFV
expressing WT APP or the indicated mutant substrates (mean±s.d., n¼3). (C–H) Statistical signiﬁcance tested with one-way ANOVA and
Dunnett’s post-test, taking the corresponding WT as control group; *Po0.05,**Po0.01.
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that ‘partial loss’ of g-secretase function at Notch or other g-
s e c r e t a s es u b s t r a t e sa c t sa sa na g g r a v a t i n gf a c t o ri nF A D .
Moreover, our Ab product proﬁles evidence the generation
of longer Ab peptides (4Ab43) by the most aggressive FAD
complexes. However, whether particular changes in the FAD
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interesting but unaddressed question.
In a ﬁnal series of experiments, we have also assessed to
what extent different g-secretase-directed drugs such as GSI
and GSM affect the three mechanisms identiﬁed in the
current work. When investigating the transition state analo-
gue L-685,458 (InhX), semagacestat, and the Notch-sparing
begacestat and avagacestat, we found that the four com-
pounds lowered all g-cleavages to a similar extent and did
not change the Ab ratios. However, when we assayed the
effects of these GSI on Notch processing, which is considered
to be the major liability of GSI, we surprisingly found that
semagacestat was more effective in inhibiting Notch than
APP. This is particularly signiﬁcant when considering that a
phase III clinical trial with semagacestat was interrupted last
year because of severe side effects including worsened cogni-
tion and increased incidence of skin cancer. Similarly, the
Notch-sparing compounds begacestat and avagacestat did not
show signiﬁcant higher selectivity for APP compared to the
Notch substrate in our assay. These data raise serious
concerns about the interpretation of inhibitory studies
that relied on cellular or in vivo data, which in general do
not allow direct quantitative comparisons as done with our
assay. Importantly, our data do not discard the selective
inhibition of APP at the e-cleavage as a plausible strategy
for drug development, but basically indicates that the ap-
proaches that have been used to reach this aim need to be
revisited.
We also tested GSMs and found that all three candidates
keep full functionality at the endopeptidase cleavage and
regulate the carboxypeptidase-like activity by activating the
fourth cycle of the g-secretase, resulting in an increased
processing of the aggregation-prone Abs towards shorter Ab
peptides. Our data, however, suggest some caution with this
strategy as the tested compounds differentially affect the
Ab484Ab38 versus the Ab494Ab40 pathway. The relative
increase of Ab38 observed with all compounds needs further
scrutiny, as APP clinical mutations also promote this produc-
tion line and our initial data provided here (Supplementary
Figure 5) suggest that Ab38 is less benign than Ab40 with
regard to its interaction with Ab42. However, further research
is needed to evaluate whether the weak (but signiﬁcant)
effects we see with Ab38 translate into an increased toxicity
in vivo.
In conclusion, our work provides an important step forward
towards the understanding of the mechanisms by which FAD
mutations in PSEN and APP cause AD. Our ﬁndings support
strongly the hypothesis that although these mutations affect
g-secretase in various ways, they all lead to qualitative shifts in
the Ab proﬁles, which provides a common denominator for the
pathogenic effect of all FAD mutations.
Materials and methods
Antibodies
Rabbit polyclonal antibodies human PSEN1–NTF (B19.3), PSEN2–
CTF (B24), APH-1a (B80.3), PEN-2 (B126.1) and APP C-terminus
(B63.3) and monoclonal 9C3 against Nicastrin have been described
(Annaert et al, 2001; Esselens et al, 2004). Rabbit monoclonal neo-
epitope AICD was obtained from Lilly Company. Other antibodies
purchased were as follows: anti-FLAG M2 from Sigma, goat-anti-
mouse IRDye800 from Rockland, goat-anti-rabbit Alexa680 from
Invitrogen, 82E1 from Demeditec Diagnostics, MAB5232 and
MAB1563 against PSEN1–CTF and human PSEN1–NTF from
Chemicon, biotinylated anti-mouse IgG from Vector laboratories,
streptavidin-HRP from GE Healthcare and 1E8 from Nanotools,
Teningen, Germany. ELISA capturing antibodies purchased were
as follows: JRF AB038 for Ab1-38 from Janssen; JRF/cAb40/28 for
Ab1-40 from Janssen; JRF/cAb42/26 for Ab1-42 from Janssen; and
Ab1-43 from Signet Labs Inc.. Detection antibody was obtained
from Jansen; huAB25-HRPO (Zhou et al, 2011).
GSI and GSM
L-685,458 (Inhibitor X) was purchased from Calbiochem.
Begacestat and the GSMs were synthesized according to the proce-
dures reported in either primary publications or patents. GSM 1 was
synthesized according to WO2006043064, GSM 2 (E-2012) accord-
ing to WO2006112552 and WO2006046575, and GSM 3 according to
WO2005115990. LY-450139 (semagacestat) and BMS-708163 (avaga-
cestat) were obtained from Haoyuan Chemexpress Co. Limited,
Shanghai.
Cell culture
Psen1/Psen2-deﬁcient (
 / ) MEF (Psen1/2
 /  mEF) (Herreman
et al, 2000) were cultured in Dulbecco’s modiﬁed Eagle’s medium/
F-12 containing 10% fetal bovine serum. Psen1/2
 /  mEF rescued
with wt (human) PSEN1 or L166P, G384A and DE9 as well as wt
(human) PSEN2 or N141I were reported before Bentahir et al
(2006). The Y115H, M139V and I213T FAD–PSEN1 cell lines were
generated accordingly. mEF–PSEN1 cell lines were transduced with
a recombinant adenovirus Ad5/CMV-APP bearing human APP-swe,
as previously described (Chavez-Gutierrez et al, 2008). Neuronal
cultures derived from E14 embryos and Semiliki Forest virus
transfection procedures have been described previously (Annaert
et al, 1999). Semliki Forest viruses (SFV) were produced as
described (Annaert et al, 1999). Brieﬂy, brains from E14 embryos
were trypsinized and plated on 6-cm dishes (Nunc) precoated with
poly-L-lysine (Sigma–Aldrich). Cultures were maintained in
neurobasal medium (Gibco) supplemented with B27 (GibcoBRL)
and 5mM cytosine arabinoside to prevent glial cell proliﬁcation.
After 3 days, neurons were transduced with SFV expressing wt or
FAD mutant APP. After 1 and 3h, post-infection media were
refreshed. After 24h, sAb were analysed by ELISA.
Expression and puriﬁcation of substrates-3xFLAG
Substrate puriﬁcation was performed as previously described
(Chavez-Gutierrez et al, 2008). Notch-, ErB4- and N-Cadherin-
based substrates were designed to be similar in size to the APP
substrate (C99–3XFLAG). Purity was assessed by SDS–PAGE and
Coomassie staining (GelCode reagent, Pierce).
In vitro activity assays using solubilized c-secretase
In vitro activity assays were done as previously described (Chavez-
Gutierrez et al, 2008), with minor modiﬁcations. MEF’s microsomal
fractions were prepared in 50mM citric acid, pH 6.7, 0.25M
Figure 6 Analysis of GSI and GSM. Dose-response inhibitory assays for (A) the transition state analogue (TSA) L-685,458 (InhX), (B)
semagacestat, and the Notch-sparing compounds (C) begacestat and (D) avagacestat (see materials in Supplementary data) were performed
using CHAPSO-extracted membranes from dKO PSEN1/2 MEFs stably expressing human wt PSEN1 as source of g-secretase and 1  Km
substrate concentrations (400nM APP-C99-3XFLAG or 1mM Notch-3XFLAG). Structures of the different compounds are displayed. In vitro-
generated AICD (in black) or NICD (in red) are plotted as percentage of control reaction (DMSO). Error bars indicate s.d. (n¼3); except for
semagacestat plot (s.e., n¼5). (E) Top panel: structures of the GSM tested. Low panel: increasing concentrations of GSM 1–3 did not change
in vitro AICD generation, neither at 0.4mM APP-C99 substrate (1  Km) nor at saturating conditions (1.75mM C99-3XFLAG). (F) Effect of
increasing concentrations of GSM 1–3 on Ab production at 1  Km APP-C99 substrate (0.4mM): Ab product/substrate ratios show that GSM
1–3 speciﬁcally activate the fourth cycle of the g-secretase complex. In particular, GSM activate the Ab38 product line. Panel shows mean±s.e.;
statistical signiﬁcance of the data (n¼4) tested with ANOVA and Dunnett’s post test, vehicle (DMSO) as control group; *Po0.05,**Po0.01.
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reactions were carried out in 50mM citric acid, pH 6.7, 0.25M
sucrose, 1mM EGTA, 1  EDTA-free complete proteinase inhibitors
(Roche), 2.5% DMSO and 0.05% phosphatidylcholine. Reactions
were incubated for 4h at 371C unless otherwise mentioned.
Lipids and substrates were extracted by adding 1 volume chloro-
form/methanol (2:1, v/v). Then, the aqueous fraction (ICD pro-
ducts) was taken and subjected to SDS–PAGE and quantitative
western immunoblot. Known amounts of C99-3XFLAG were in-
cluded as standards for absolute quantiﬁcations. ICD-3XFLAG and
standards were determined with the anti-FLAG M2 and goat-anti-
mouse IR800 antibodies, whereas the AICD50–99 product was de-
termined with a neo-epitope mAb and a goat-anti-rabbit Alexa680
secondary antibody. Infrared signals were detected using the
Odyssey Infrared Imaging System.
Calculation of kinetics constants
Kinetic constants were estimated by nonlinear curve-ﬁtting using
GraphPad Prism 4 software. The equation V¼(Vmax [S])/
(Kmþ[S]) was used to calculate apparent Km and Vmax values
for the different enzymes, where V was experimentally determined
using a range of substrate concentrations [S]. g-Secretase activities
were normalized to PSEN–CTF fragment levels or full-length PS1
levels for the DE9 mutant.
Quantiﬁcation of soluble Ab using sandwich ELISA
Ninety-six-well plates (NUNC) were coated with 1.5mg/ml Ab
capture antibody, excepting Ab43-ab coated at 7.5mg/ml, in a
ﬁnal volume of 50ml buffer (10mMTris HCl, 10mM NaCl, 10mM
NaN3, pH 8.5). After overnight incubation at 41C, the plates were
rinsed with PBSþ0.05% Tween 20 and blocked with 100ml per well
of casein buffer (1g casein in 1l 1 PBS, pH7.4) for 4h at room
temperature. Samples and standards (synthetic human Ab1-38,
Ab1-40, Ab1-42 or Ab1-43 peptides) were diluted in casein buffer.
After overnight incubation at 41C, plates were rinsed and developed
using 50ml per well of 100mM NaAC pH 4.9/TMB (Sigma)/H2O2.
Reactions were stopped with 50ml per well of 2N H2SO4 and read on
a Perkin Elmer Envision 2103 multilabel reader at 450nm.
Urea gels
Ab-peptides were analysed by a modiﬁed version of the urea-based
SDS–PAGE (10% T/5% C instead of 12%T/5% C polyacrylamide
and 0.075M instead of 0.1M H2SO4 in the separation gel) (Wiltfang
et al, 2002). Western immunoblot was done using 1E8, amplifying
the signal with biotinylated anti-mouse IgG and streptavidin-HRP.
Signals were detected using ECL chemiluminescence with an Intas
Imager (Intas, Go ¨ttingen, Germany).
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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